-
1.发明公开SOLUBLE POLYPEPTIDES FOR USE IN TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS 审中-公开可溶性多肽FOR USE在自身免疫性疾病和炎性的治疗
公开(公告)号：EP2379584A1
公开(公告)日：2011-10-26
申请号：EP09796708.7
申请日：2009-12-17
申请人： Novartis AG
IPC分类号： C07K14/435 , A61K38/17 , C07K14/705 , C12N1/15 , C12N1/21 , C12N5/10 , C12N15/68
CPC分类号： C07K14/4703 , A61K38/00
摘要： The present invention relates to soluble CD47 binding polypeptides, for use as a medicament, in particular for the prevention or treatment of autoimmune and inflammatory disorders, for example allergic asthma and inflammatory bowel diseases. The Invention more specifically relates to a soluble CD47 binding polypeptide for use as a medicament, comprising an extracellular domain of SIRPα (CD172a) or functional derivatives which bind to human CD47.
-
公开(公告)号：EP2315780B8
公开(公告)日：2015-09-23
申请号：EP09797499.2
申请日：2009-07-15
申请人： Novartis AG
发明人： HEUSSER, Christoph , NEUGEBAUER, Julia , SCHAADT, Eveline , URLINGER, Stefanie , WOISETSCHLAEGER, Maximilian
IPC分类号： C07K16/28 , A61K39/395 , A61P37/06 , A61P19/02
CPC分类号： C07K16/2878 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/74 , C07K2317/76
-
公开(公告)号：EP2648750A2
公开(公告)日：2013-10-16
申请号：EP11808178.5
申请日：2011-12-08
申请人： Novartis AG
发明人： COSENZA, Marta , HEUSSER, Christoph , NEUGEBAUER, Julia , SCHAADT, Eveline , URLINGER, Stefanie , WOISETSCHLAEGER, Maximilian
IPC分类号： A61K39/395 , A61K9/19
CPC分类号： C07K16/2878 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K39/39533 , A61K39/3955 , A61K39/39591 , A61K47/10 , A61K47/183 , A61K47/26 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73
摘要： Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.
摘要翻译： 抗BAFFR抗体配制成冻干液或液体制剂。 可以重构冻干物以产生具有高浓度抗体活性成分的溶液，用于递送至患者，而不会有高水平的抗体聚集。 所述冻干物质可以用水重构物重构以提供其中抗体具有至少50mg / ml浓度的水性组合物。 冻干物或水性药物组合物可以包括糖，缓冲剂，表面活性剂和/或游离氨基酸中的一种或多种。
-
公开(公告)号：EP2315780A1
公开(公告)日：2011-05-04
申请号：EP09797499.2
申请日：2009-07-15
申请人： Novartis AG
发明人： HEUSSER, Christoph , NEUGEBAUER, Julia , SCHAADT, Eveline , URLINGER, Stefanie , WOISETSCHLAEGER, Maximilian
IPC分类号： C07K16/28 , A61K39/395 , A61P37/06 , A61P19/02
CPC分类号： C07K16/2878 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/74 , C07K2317/76
摘要： The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.
-
5.发明公开
公开(公告)号：EP3638692A1
公开(公告)日：2020-04-22
申请号：EP18742595.4
申请日：2018-06-08
申请人： Novartis AG
-
公开(公告)号：EP2648750B1
公开(公告)日：2017-01-25
申请号：EP11808178.5
申请日：2011-12-08
申请人： Novartis AG
发明人： COSENZA, Marta , HEUSSER, Christoph , NEUGEBAUER, Julia , SCHAADT, Eveline , URLINGER, Stefanie , WOISETSCHLAEGER, Maximilian
CPC分类号： C07K16/2878 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K39/39533 , A61K39/3955 , A61K39/39591 , A61K47/10 , A61K47/183 , A61K47/26 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73
-
公开(公告)号：EP2315780B1
公开(公告)日：2015-08-19
申请号：EP09797499.2
申请日：2009-07-15
申请人： Novartis AG
发明人： HEUSSER, Christoph , NEUGEBAUER, Julia , SCHAADT, Eveline , URLINGER, Stefanie , WOISETSCHLAEGER, Maximilian
IPC分类号： C07K16/28 , A61K39/395 , A61P37/06 , A61P19/02
CPC分类号： C07K16/2878 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/74 , C07K2317/76
-
8.发明公开PHENYL-(4-PHENYL-PYRIMIDIN-2-YL)-AMINES FOR ENHANCING IMMUNOTOLERANCE 审中-公开苯基 - （4-苯基 - 嘧啶-2-基）胺以提高免疫耐受
公开(公告)号：EP1933839A1
公开(公告)日：2008-06-25
申请号：EP06792292.2
申请日：2006-09-27
申请人： Novartis AG
IPC分类号： A61K31/505 , A61K35/28 , C12N5/08 , A61P37/06
CPC分类号： A61K39/001 , A61K31/505 , A61K2039/5154 , A61K2039/55511
摘要： The use of a phenyl-(4-phenyl-pyrimidin-2-yl)-amine for the preparation of a medicament for enhancing immunotolerance in a mammal; and uses, methods, processes and pharmaceutical combinations and compositions comprising such phenyl-(4-phenyl-pyrimidin-2-yl)-amine.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.014 秒)
